Deprecated!
This application is deprecated. Please use the latest version of the tool here.
Please cite:
I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I. Kanellos, I-L. Anastasopoulos, S. Maniou, K. Karathanou, D. Kalfakakou, A. Fevgas, T. Dalamagas and A. G. Hatzigeorgiou. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucl. Acids Res. (2014)
Data Download:
DIANA-TarBase v7 is available for scientific non-profit and non-commercial use! Download TarBase v7 by following this link
|
||||||||
Related Pathways
Publication year
Prediction score
Filters
Selected:
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Remove all 
Species
Method Type
Method
Regulation type
Validation type
Validated as
Source
Publication year
Prediction score
Loading... |
| Wait until the result set is completed... |
Gene name
miRNA name
Methods
Pred.Score
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:23761783-23761806 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:23761783-23761806 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:23761783-23761806 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:64147983-64148011 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:6466222-6466243 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:6462266-6462289 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:6462266-6462289 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:154010574-154010596 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:31830173-31830189 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:31830173-31830189 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:31830173-31830189 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:31830173-31830189 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr6:31830173-31830189 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:31830173-31830189 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:117522984-117523012 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:37298846-37298872 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr3:37366619-37366644 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:167041094-167041122 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:167042361-167042384 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr20:36785135-36785161 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
UNKNOWN
Microarrays
POSITIVE
INDIRECT
TarBase 6.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:21058465-21058489 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21057372-21057394 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr19:21058881-21058900 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21057372-21057394 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: NL4-3) infected CD4+ T-cell Line. length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:80487690-80487717 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:205774848-205774874 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr20:49089255-49089277 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49089255-49089277 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr20:49092073-49092100 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49089255-49089277 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49092073-49092100 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49092073-49092100 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49089255-49089277 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49089255-49089277 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr20:49089255-49089277 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:120438997-120439003 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:120438997-120439003 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:158628425-158628449 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:158635386-158635394 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:158635386-158635394 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:113026413-113026435 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr21:42908881-42908903 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:88199227-88199250 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:88199227-88199250 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:88199227-88199250 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:23985060-23985082 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr15:89888610-89888626 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:46139786-46139809 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:27497069-27497076 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:27497069-27497076 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:27497069-27497076 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:27497069-27497076 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:95514245-95514256 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CHD1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:98856175-98856199 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:98856175-98856199 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:98856099-98856125 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
C1orf85 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:156294931-156294955 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KTN1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:55641148-55641174 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CSNK1E (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:38302965-38302990 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
LITAF (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:11548192-11548219 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZNF43 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808674-21808698 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808288-21808310 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808288-21808310 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808842-21808866 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808288-21808310 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808288-21808310 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808288-21808310 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:21808204-21808226 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
LAP3 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:17588888-17588913 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CALCOCO1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:53725140-53725164 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZNF587B (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:57841954-57841976 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PRPF8 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:1679055-1679077 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:1676632-1676659 (UNKNOWN)
Breast carcinoma cell line, triple negative. 3 replicates available.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr17:1679055-1679077 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
IDH1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:208236465-208236492 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MRPL23 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:1952809-1952835 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
UTP18 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:51288132-51288155 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DCTN2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:57533993-57534015 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CSDE1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:114749852-114749872 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr1:114749852-114749872 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ABCC5 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:183986703-183986725 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CFLAR (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:201170952-201170973 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:201170952-201170973 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MKL2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:14263906-14263931 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZNF680 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:64520455-64520480 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr7:64520455-64520480 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RMND5A (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:86774596-86774619 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FKBP2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:64242528-64242556 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr11:64242528-64242556 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
UBR4 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:19093341-19093363 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
UBLCP1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:159275199-159275221 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZNF703 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:37698741-37698766 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr8:37698741-37698766 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MDM2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:68842943-68842965 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:68842943-68842965 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KTI12 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:52033512-52033539 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PLOD1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:11966257-11966284 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DYRK1A (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr21:37512511-37512536 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:37516771-37516792 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:37516771-37516792 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:37512416-37512433 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:37516771-37516792 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:37516771-37516792 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PDE7A (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:65718476-65718496 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
HNRNPA2B1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:26192152-26192179 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:26200670-26200691 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:26200670-26200691 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NFIA (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:61456409-61456433 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:61456409-61456433 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:61456409-61456433 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
WDR4 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr21:42849330-42849353 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
EIF4G3 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:20941673-20941700 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TULP4 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:158502278-158502300 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PDIK1L (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:26122227-26122254 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
COPG1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:129277445-129277467 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr3:129277445-129277467 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr3:129277445-129277467 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MTHFR (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:11786327-11786351 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PPIL4 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:149512178-149512197 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RBM26 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:79311979-79312000 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CCDC47 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:63756488-63756512 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SLIRP (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:77715820-77715848 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:77715820-77715848 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr14:77715820-77715848 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MAMDC2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr9:70168746-70168767 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
LRP8 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:53246772-53246793 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:53246967-53246994 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:53246967-53246994 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:53246967-53246994 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RPS11 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr19:49497955-49497979 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: NL4-3) infected CD4+ T-cell Line. length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SMCHD1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr18:2802775-2802798 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GATC (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:120463464-120463489 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CC2D1B (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:52353085-52353107 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TLR5 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:223109903-223109928 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ILF3 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:10681099-10681127 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FAM105A (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:14610273-14610296 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
LIPA (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:89213671-89213680 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KRIT1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:92235512-92235538 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FAM46A (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:81747982-81748008 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RICTOR (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:38949838-38949862 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:38941757-38941779 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GIGYF1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:100688872-100688894 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
HIST1H2BD (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:26158147-26158169 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:26158147-26158169 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr6:26158147-26158169 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GRTP1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:113324370-113324397 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GOLM1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr9:86033357-86033385 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PCDH10 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:133150250-133150278 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:133192212-133192236 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:133192212-133192236 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KCNJ14 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:48466023-48466047 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SRGAP1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:64086998-64087024 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CDKN1B (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:12721177-12721184 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NELFB (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr9:137266977-137267004 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr9:137263115-137263141 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GAN (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:81383046-81383074 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
BACH1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
Primary effusion lymphoma cell line BC-3
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr21:29345091-29345117 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
UTP14C (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:52032751-52032773 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FBF1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:75937542-75937563 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CHST11 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:104760337-104760365 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TSC22D3 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:107713549-107713572 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:107713549-107713572 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:107713549-107713572 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:107713549-107713572 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:107713549-107713572 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:107713549-107713572 (UNKNOWN)
AGO2 immunoprecipitation using anti-Ago2 antibody (Abcam AB57113). This antibody also recognizes Ago1 and Ago3. HIV-1 (strain: NL4-3) infected CD4+ T-cell Line. length of infection (days): 3.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
E2F2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:23530658-23530680 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CBX2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:79784198-79784221 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
WDR12 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:202911957-202911982 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MPC2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:167917186-167917207 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RNF44 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:176530624-176530646 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
EDRF1 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:125733651-125733674 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NT5DC2 (hsa)
hsa-miR-142-3p
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:52528905-52528933 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr3:52528905-52528933 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0